Tianjin JuveStar Enters $74 Million Deal with Raziel for Body Fat Treatment

Tianjin JuveStar Biotech, a Fosun Pharma affiliate, acquired Greater China rights to an aesthetic product from Israel 's Raziel Therapeutics in a $74 million agreement. RZL-012 is an injectable drug initially indicated to treat moderate to significant submental fullness, known commonly as a double-chin. Raziel expects to test the product in other body fat indications in the future. Fosun has invested in JuveStar and is incubating the company. More details.... Stock Symbols: (SHA: 600196; HK: 02196) Share this with colleagues: // //
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.